Table 1.
Baseline epidemiological and clinical characteristics of the enrolled patients.
Table 2.
Baseline epidemiological and clinical characteristics according to dose in patients treated with pirfenidone (n = 100).
Fig 1.
Overall survival of IPF patients on pirfenidone and no-antifibrotic treatment.
Fig 2.
Overall survival of IPF patients according to the pirfenidone dose–full recommended dose of 1800 mg/day vs. relatively low-dose of 1200 mg/day or less.
Table 3.
Effects of pirfenidone treatment on mortality using Cox proportional hazard regression model.
Table 4.
Comparison of pirfenidone treatment and annual decline in pulmonary function.
Table 5.
Comparison of annual decline in pulmonary function between patients who were not treated with antifibrotic drugs and patients who were treated with full recommended dose of pirfenidone (1800mg/d).
Table 6.
Comparison of annual decline in pulmonary function between patients who were not treated with antifibrotic drugs and patients who were treated with relatively low dose of pirfenidone (600mg/d or 1200mg/d).
Table 7.
Comparison of annual decline in pulmonary function between patients who were treated with full recommended dose of pirfenidone (1800mg/d) and relatively low dose of pirfenidone (600mg/d or 1200mg/d).
Table 8.
Comparison of incidence of adverse events between patients who were treated with full recommended dose of pirfenidone (1800mg/d) and relatively low dose of pirfenidone (600mg/d or 1200mg/d).
Table 9.
Comparison of cause of pirfenidone discontinuation between patients who were treated with full recommended dose of pirfenidone (1800mg/d) and relatively low dose of pirfenidone (600mg/d or 1200mg/d).